Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML-Reference-Cited by-同舟云学术

Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML

Published:2012-06 Issue:6 Volume:36 Page:756-763
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Nair Rajesh R.,Tolentino Joel H.,Argilagos Raul F.,Zhang Ling,Pinilla-Ibarz Javier,Hazlehurst Lori A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference27 articles.

1. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products;Lugo;Science (New York, NY),1990

2. Evaluating the effect of P210 BCR/ABL on growth of hematopoietic progenitor cells and its role in the pathogenesis of human chronic myelogenous leukemia;Gishizky;Seminars in Hematology,1993

3. A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice;Johnson;PloS One,2009

4. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia;Hochhaus;Leukemia,2009

5. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R);Kantarjian;Cancer,2009

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature;Expert Opinion on Pharmacotherapy;2024-07-02

2. Future Directions in Chronic Phase CML Treatment;Current Hematologic Malignancy Reports;2021-10-14

3. Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers;Cancers;2021-10-14

4. Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review;Current Research in Translational Medicine;2021-07

5. Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells;Archives of Medical Science;2021-01-05